Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 3 1Phase 2/3 1Phase 2 1

Status

Completed 129Terminated 44Recruiting 41Unknown 31Active not recruiting 19Withdrawn 11Not yet recruiting 9Suspended 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2

Interventions

pembrolizumab 3Drug Therapy 3Vincristine 2S 1 (combination) 2Nivolumab 2Gemcitabine 2Cyclophosphamide 2CA-4948 2Bevacizumab 2zimberelimab 1venetoclax 1tivozanib 1titanium silicide 1tisagenlecleucel 1sotigalimab 1propranolol CR 1prednylidene 1pimonidazole 1palbociclib 1mirdametinib 1imisopasem manganese 1gusacitinib 1fludarabine 1deltacortene 1brincidofovir 1axicabtagene ciloleucel 1atezolizumab 1Testosterone Propionate 1Testosterone 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Suspended × Gemcitabine × Clear all
NCT03417921 2025-10-01

Pancreatic

Ability Pharmaceuticals SL

Phase 1/2 Suspended
60 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00209677 2007-11-01

Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Hokkaido Gastrointestinal Cancer Study Group

Phase 1/2 Suspended
40 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡